SMR 2019: After 5 Years, Cobimetinib + Vemurafenib Continues to Provide Long-Term Clinical Benefit in BRAF V600-Mutated Metastatic Melanoma
No late treatment safety concerns were observed.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.